Nu Skin Enterprises (NUS) Current Deferred Revenue (2015 - 2025)

Nu Skin Enterprises (NUS) has 11 years of Current Deferred Revenue data on file, last reported at $12.7 million in Q4 2025.

• For the quarter ending Q4 2025, Current Deferred Revenue fell 18.81% year-over-year to $12.7 million; the trailing twelve-month figure through Dec 2025 stood at $12.7 million (down 18.81% YoY), and the FY2025 full-year result was $12.7 million, down 18.81% from the prior year.
• Current Deferred Revenue declined to $12.7 million in Q4 2025, from $15.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $33.1 million in Q4 2021 to a low of $12.7 million in Q4 2025.
• A 5-year average of $21.8 million and a median of $20.3 million in 2023 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue retreated 5.46% in 2021 and slipped 24.82% in 2023, its largest moves.
• Tracing NUS's Current Deferred Revenue over 5 years: stood at $33.1 million in 2021, then decreased by 18.37% to $27.1 million in 2022, then fell by 24.82% to $20.3 million in 2023, then declined by 22.86% to $15.7 million in 2024, then slipped by 18.81% to $12.7 million in 2025.
• Business Quant data shows NUS's Current Deferred Revenue at $12.7 million in Q4 2025, $15.7 million in Q4 2024, and $20.3 million in Q4 2023.